.jpeg)
{{ variable.name }}
Opicapone is a peripherally selective, reversible catechol-O-methyltransferase (COMT) inhibitor. By inhibiting COMT enzyme activity, it reduces the peripheral metabolism of levodopa, thereby prolonging its action time and enhancing its efficacy.
1. Generic name :Opicapone (Opicapone)
2. Trade name :ONGENTYS®
3. Dosage form : Capsule
4. Main ingredients : Each capsule contains 25 mg or 50 mg of opicapone (in the form of ethanesulfonate), and excipients include lactose, magnesium stearate, pregelatinized starch, etc.
Parkinson's disease (PD) : As an adjuvant treatment with levodopa/carbidopa, it is used to relieve the "off period" symptoms of PD patients.
1. Specifications : 25mg (light blue opaque capsules, printed with "OPC25" blue logo) and 50mg (dark blue opaque capsules, printed with "OPC50" white logo).
2. Characteristics of : The content is bright yellow powder, which becomes a uniform suspension after reconstitution.
1. Recommended dosage of : 50mg once a day, taken orally before going to bed.
2. Dietary requirements : Fasting 1 hour before taking the medicine and at least 1 hour after taking the medicine.
3. What to do if you miss a dose : If you miss a dose, take it according to the originally planned time the next day, and there is no need to make up for it.
1. Hepatic insufficiency : Adjust to 25 mg once a day for moderate hepatic insufficiency (Child-PughB); disabled for severe hepatic insufficiency (Child-PughC).
2. Adverse reaction adjustment : If severe diarrhea or liver enzyme elevation occurs, the dose can be reduced to 25mg or the administration can be suspended.
1. Cardiovascular risk : Combined use of COMT metabolic drugs (such as epinephrine) may cause arrhythmia or blood pressure fluctuations, and requires close monitoring.
2. Daytime sleepiness : Avoid driving or operating machinery while taking medication.
3. Blood pressure monitoring : Hypotension or syncope may occur, and regular check-ups are required.
4. Psychiatric symptoms : Be wary of hallucinations, impulsive behaviors, etc., and discontinue medication when they occur.
1. Pregnant women: : Disabled (animal experiments show fetal toxicity).
2. Lactation : Stop breastfeeding during treatment.
3. Children : Safety has not been established.
4. U200c for the elderly: No dose adjustment is required for those aged ≥65 years.
1. Common (≥4%) : Dyskinesia (20%), constipation (6%), increased creatine kinase (5%), hypotension (5%), weight loss (4%).
2. Severe reactions : Hepatotoxicity, myocardial infarction (rare).
1. Combined use of non-selective MAO inhibitors (such as phenelzine);
2. Patients with pheochromocytoma or paraganglioma.
1. MAO inhibitor : Prohibited combination (increases cardiovascular risk);
2. COMT metabolism drug : may enhance its effect, so combination use with caution is required.
Store unopened capsules in a dry place below 30°C (86°F) and away from light.
Original manufacturer :BIAL-Portela&Ca, S.A. (Portugal);
Note : If persistent movement disorders or mental symptoms occur during treatment, you should seek medical treatment immediately. Quitting smoking may improve the effectiveness of medications.